ACOG practice bulletin. Prevention of Rh D alloimmunization. Number 4, May 1999 (replaces educational bulletin Number 147, October 1990). Clinical management guidelines for obstetrician-gynecologists. American College of Obstetrics and Gynecology.
The reduction in the incidence of Rh D alloimmunization is a prototype for the effectiveness of preventive medicine. Some controversies remain, however, such as the use of anti-D immune globulin in patients with either threatened abortion or antenatal hemorrhage. Similarly, it may not be cost-effective either to screen all Rh D-negative patients with an indirect Coombs test at 24-28 weeks of gestation or to screen all postpartum patients for excessive fetomaternal hemorrhage.
D003362:Cost-Benefit Analysis; D004363:Drug Utilization / Q000592:standards; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007519:Isoantigens / Q000276:immunology; D011247:Pregnancy; D011248:Pregnancy Complications; D011295:Prenatal Care; D012203:Rh Isoimmunization / Q000191:economics / Q000517:prevention & control*; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage* / Q000191:economics
D007519:Isoantigens; D018029:Rho(D) Immune Globulin